LES RÉTICULOSES PROLIFÉRATIVES DU NEVRAXE (À PROPOS d'UN CAS ANATOMO-CLINIQUE d'ENCÉPHALITE Réticulo-Granulomateuse)

Sigwald, J; Chomette, G; Bouttier, D

doi:10.1016/b978-1-4832-0077-4.50032-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, increased DA turnover (Carlsson, 1987) often induces extrapyramidal side-effects both in experimental animals (Deneau and Crane, 1969;Paulson, 1972;Messiha, 1974) and in the susceptible schizophrenics as well as in other psychiatric patients (Sigwald et al, 1959;Ayd, 1961;Crane, 1968). Thus it appears that changes in DA turnover have been consistently linked to adverse reaction in the schizophrenic subject.…”

Section: Discussionmentioning

confidence: 87%

Modulation of mouse brain dopamine, serotonin and metabolites by methionine: Implications for schizophrenia and genetics

Messiha

1991

Human Psychopharmacology

View full text Add to dashboard Cite

The effect of methionine, an essential amino acid, on brain regional distribution of dopamine, serotinin and major acidic metabolites was studied in two genetically different strains of mice. These were the inbred albino BALB/C and the black C,,BL/6 mouse strains. The later strain was more sensitive than the former mouse strain to the methionine treatment. This has been demonstrated by methionine-produced change in dopamine metabolites in cerebellum, cortex and medulla regions, which suggests a decrease in dopamine turnover in the C,,BL/6 mice. Conversely, methionine-mediated changes in BALB/C mouse medullary region was suggestive of an increase in dopamine turnover. Little changes occurred in cerebral serotonin or 5-hydroxyindoleacetic acid levels, except for an increased serotonin in Cs7BL/6 mouse midbrain region. The results suggest that methionine possesses CNS pharmacological property pertaining to dopamine, other than its well-known action as a methyl donor in transmethylation processes, which is genotypic-dependent. Alternatively, modulation of the monoamines by methionine may explain its antidepressant property and possible contribution to the pharmacological hypotheses relevant to the biology of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 87%

Modulation of mouse brain dopamine, serotonin and metabolites by methionine: Implications for schizophrenia and genetics

Messiha

1991

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…23 24 However, only tardive dyskinesia, dystonia, and akathisia are described as TSs in the DSM-V. 14 The term “classic tardive dyskinesia” was introduced to describe the prototypical orobuccolingual stereotypic or choreoathetoid movements. 25 26 However, it can also be used as an umbrella term in the literature to include a variety of movement disorders such as akathisia, dystonia, tremor, tics, chorea, and myoclonus, which has led to confusion. 27 Additionally, it is critical to differentiate classic tardive dyskinesia from tardive dystonia, as anticholinergic drugs tend to worsen classic tardive dyskinesia but may help patients with tardive dystonia.…”

Section: Phenomenology and Temporalitymentioning

confidence: 99%

Drug-Induced Movement Disorders

et al. 2023

View full text Add to dashboard Cite

Drug-induced movement disorders (DIMDs) are most commonly associated with typical and atypical antipsychotics. However, other drugs such as antidepressants, antihistamines, antiepileptics, antiarrhythmics, and gastrointestinal drugs can also cause abnormal involuntary movements. Different types of movement disorders can also occur because of adverse drug reactions. Therefore, the important key to diagnosing DIMDs is a causal relationship between potential offending drugs and the occurrence of abnormal movements. The pathophysiology of DIMDs is not clearly understood; however, many cases of DIMDs are thought to exert adverse mechanisms of action in the basal ganglia. The treatment of some DIMDs is quite challenging, and removing the offending drugs may not be possible in some conditions such as withdrawing antipsychotics in the patient with partially or uncontrollable neuropsychiatric conditions. Future research is needed to understand the mechanism of DIMDs and the development of drugs with better side-effect profiles. This article reviews the phenomenology, diagnostic criteria, pathophysiology, and management of DIMDs.

show abstract

LES RÉTICULOSES PROLIFÉRATIVES DU NEVRAXE (À PROPOS d'UN CAS ANATOMO-CLINIQUE d'ENCÉPHALITE Réticulo-Granulomateuse)

Cited by 2 publications

References 0 publications

Modulation of mouse brain dopamine, serotonin and metabolites by methionine: Implications for schizophrenia and genetics

Modulation of mouse brain dopamine, serotonin and metabolites by methionine: Implications for schizophrenia and genetics

Drug-Induced Movement Disorders

Contact Info

Product

Resources

About